AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8831308 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg bupivacaine, 1.5 mL of the 0.5% spinal bupivacaine + 1.5 mL saline
Number of subjects: 60
Study 8831308 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bupivacaine, 1 mL of the 0.5% spinal bupivacaine + 2 mL saline
Number of subjects: 60
Study 1481758 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosurgical operations
Number of subjects: 470
Study 1481758 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical operations without pre-existing infection
Number of subjects: 470
Study 29140772 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integration of oncology and palliative care (EIPC)
Number of subjects: 350
Study 29140772 — intervention group
Group type: COMPARATOR
Intervention: Usual oncology care
Number of subjects: 350
Study 27806980 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (observational study, no intervention reported)
Number of subjects: 3338
Study 24836052 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad® application social script intervention (n=16)
Number of subjects: 32
Study 24836052 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 32
Study 23257028 — intervention group
Group type: EXPERIMENTAL
Intervention: HUCMSCs
Number of subjects: 13
Study 23257028 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 20691130 — intervention group
Group type: EXPERIMENTAL
Intervention: enteric-coated lactoferrin (eLF) 300 mg/d
Number of subjects: 26
Study 20691130 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 18467726 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha (300 microg) administered once per week for 4 weeks then every 3 weeks for up to six cycles of chemotherapy
Number of subjects: 600
Study 18467726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 18467726 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha
Number of subjects: 600
Study 16964522 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT; 25 mg) monotherapy
Number of subjects: 0
Study 16964522 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT + Enalapril (10 mg)
Number of subjects: 0
Study 16964522 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT + Candesartan (8 mg)
Number of subjects: 0
Study 16964522 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT + Amlodipine (5 mg)
Number of subjects: 0
Study 16964522 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT + Propranolol (80 mg)
Number of subjects: 0
Study 16964522 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT + Bisoprolol (5 mg)
Number of subjects: 0
Study 16964522 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT + Diclofenac (50 mg)
Number of subjects: 0
Study 16964522 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT + Rofecoxib (25 mg)
Number of subjects: 0
Study 12706200 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency ultrasound (US) at low intensity (0 micro m) with HAES 0.1%, 1%, or 2%
Number of subjects: 3
Study 12706200 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency ultrasound (US) at medium intensity (144 micro m) with HAES 0.1%, 1%, or 2%
Number of subjects: 3
Study 12706200 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency ultrasound (US) at high intensity (192 micro m) with HAES 0.1%, 1%, or 2%
Number of subjects: 3
Study 12706200 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency ultrasound (US) at none intensity (0 micro m) with normal saline
Number of subjects: 3
Study 10714840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine (200 mg in 200 ml saline)
Number of subjects: 50
Study 10714840 — intervention group
Group type: COMPARATOR
Intervention: Control (200 ml saline)
Number of subjects: 50
Study 8833706 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (TU I)
Number of subjects: 10
Study 8833706 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline with amino acids infusion (TU II)
Number of subjects: 10
Study 8833706 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline with heparin infusion (TU III)
Number of subjects: 10
Study 1435158 — intervention group
Group type: COMPARATOR
Intervention: Round chainring
Number of subjects: 11
Study 1435158 — intervention group
Group type: EXPERIMENTAL
Intervention: Shimano Biopace
Number of subjects: 11
Study 1435158 — intervention group
Group type: EXPERIMENTAL
Intervention: Eng10 elliptical chainring
Number of subjects: 11
Study 1435158 — intervention group
Group type: EXPERIMENTAL
Intervention: Eng90 elliptical chainring
Number of subjects: 11
Study 2485264 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline hypertensive group
Number of subjects: 29
Study 2485264 — intervention group
Group type: COMPARATOR
Intervention: Resting baroreflex sensitivity
Number of subjects: 29
Study 31471173 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting (ADF)
Number of subjects: 0
Study 31471173 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 29504981 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support tool linked to digital clinical history
Number of subjects: 287
Study 29504981 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 287
Study 26960245 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg tiotropium (2 puffs of 2.5 μg)
Number of subjects: 398
Study 26960245 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 μg tiotropium (2 puffs of 1.25 μg)
Number of subjects: 398
Study 26960245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 puffs)
Number of subjects: 398
Study 26960245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tiotropium doses
Number of subjects: 398
Study 25034562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (180 mg at week 0 followed by 90 mg every 8 weeks)
Number of subjects: 0
Study 25034562 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (200 mg at week 0 followed by 100 mg every 4 weeks)
Number of subjects: 0
Study 25034562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25034562 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 0
Study 23144826 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/d)
Number of subjects: 17
Study 23144826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 20439572 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine
Number of subjects: 38546
Study 20439572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38546
Study 18494970 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (Kuraray)
Number of subjects: 1
Study 18494970 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond 2 (3M ESPE)
Number of subjects: 1
Study 16555581 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (15 mg/day)
Number of subjects: 91
Study 16555581 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/day)
Number of subjects: 91
Study 12439788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg once-daily + diet
Number of subjects: 251
Study 12439788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once-daily + diet
Number of subjects: 251
Study 12439788 — intervention group
Group type: COMPARATOR
Intervention: Placebo + diet
Number of subjects: 251
Study 10051730 — intervention group
Group type: EXPERIMENTAL
Intervention: Good slides (<20% squamous cells and >50% viability; n = 24)
Number of subjects: 38
Study 10051730 — intervention group
Group type: EXPERIMENTAL
Intervention: Low viability slides (<50% viability; n = 10)
Number of subjects: 38
Study 10051730 — intervention group
Group type: EXPERIMENTAL
Intervention: High squamous cell contamination slides (>20% squamous cells; n = 8)
Number of subjects: 38
Study 10051730 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of all slides
Number of subjects: 38
Study 7655389 — intervention group
Group type: EXPERIMENTAL
Intervention: DNAemia detection by semi-nested PCR
Number of subjects: 162
Study 7655389 — intervention group
Group type: COMPARATOR
Intervention: Viremia detection using shell vial assay
Number of subjects: 162
Study 1971591 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol, 200 mg b.d.
Number of subjects: 178
Study 1971591 — intervention group
Group type: COMPARATOR
Intervention: Digoxin, 0.125 mg b.d. or t.d.
Number of subjects: 178
Study 7198463 — intervention group
Group type: EXPERIMENTAL
Intervention: Plafibride (1600 mg/d)
Number of subjects: 0
Study 7198463 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA, 1600 mg/d)
Number of subjects: 0
Study 31282782 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Z-palatopharyngoplasty (ZPPP) and partial glossectomy via 70-degree endoscopy-assisted coblation (Eco-TBR)
Number of subjects: 22
Study 31282782 — intervention group
Group type: COMPARATOR
Intervention: Multi-level surgery group
Number of subjects: 22
Study 28114246 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-12-supplemented yogurt
Number of subjects: 60
Study 28114246 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented control yogurt
Number of subjects: 60
Study 25446409 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plates (VP)
Number of subjects: 74
Study 25446409 — intervention group
Group type: COMPARATOR
Intervention: External fixation (EF)
Number of subjects: 74
Study 23504941 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min classroom-based activity break (Bizzy Break!)
Number of subjects: 90
Study 23504941 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activity break)
Number of subjects: 90
Study 23504941 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intervention and control groups
Number of subjects: 90
Study 21355071 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 0
Study 21355071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19407228 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial arterial stenosis
Number of subjects: 569
Study 19407228 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke out of the territory of the symptomatic artery
Number of subjects: 569
Study 17295723 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-induced craving
Number of subjects: 20
Study 17295723 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cue-induced craving
Number of subjects: 20
Study 17295723 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress exposure
Number of subjects: 20
Study 17295723 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cue exposure
Number of subjects: 20
Study 15661224 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m(2) on days 1 and 8 and carboplatin AUC 4 on day 1 every 21 days for up to six cycles
Number of subjects: 40
Study 11903104 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG in ARSwE group
Number of subjects: 78
Study 11903104 — intervention group
Group type: COMPARATOR
Intervention: EEG abnormality
Number of subjects: 78
Study 11903104 — intervention group
Group type: COMPARATOR
Intervention: EEG normality
Number of subjects: 78
Study 11903104 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG findings
Number of subjects: 78
Study 10087798 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic therapy
Number of subjects: 0
Study 10087798 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 7784970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruloplasmin
Number of subjects: 0
Study 7784970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2112616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (50 mg on day 3 and 25 mg on day 6)
Number of subjects: 10
Study 2112616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 10
Study 2112616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7451151 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin and probenecid (4 million IU depot penicillin i.m. + 1 g probenecid orally)
Number of subjects: 19
Study 7451151 — intervention group
Group type: COMPARATOR
Intervention: Probenecid given 30 min prior to penicillin administration
Number of subjects: 19
Study 31365792 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond UniversalTM 2‐component adhesive
Number of subjects: 56
Study 31365792 — intervention group
Group type: COMPARATOR
Intervention: ScotchbondTM Universal single‐component adhesive
Number of subjects: 56
Study 28500554 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT + TD
Number of subjects: 71
Study 28500554 — intervention group
Group type: COMPARATOR
Intervention: TD
Number of subjects: 71
Study 26341878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg) plus control treatment (acetaminophen, 400 mg, and codeine phosphate powder, 20 mg)
Number of subjects: 50
Study 26341878 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (acetaminophen, 400 mg, and codeine phosphate powder, 20 mg)
Number of subjects: 50
Study 23633146 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxylamine hydrogen succinate 12.5 mg
Number of subjects: 12
Study 23633146 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxylamine hydrogen succinate 25 mg
Number of subjects: 12
Study 23633146 — intervention group
Group type: COMPARATOR
Intervention: Doxylamine hydrogen succinate 12.5 mg vs 25 mg
Number of subjects: 12
Study 21307137 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (ExQW) 2 mg for 24 weeks
Number of subjects: 252
Study 21307137 — intervention group
Group type: COMPARATOR
Intervention: Exenatide twice daily (ExBID) 5 μg for 4 weeks followed by 10 μg for 20 weeks
Number of subjects: 252
Study 19824074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-in nonresponders (346 patients)
Number of subjects: 535
Study 19824074 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakthrough/relapse patients (78 patients)
Number of subjects: 535
Study 19824074 — intervention group
Group type: EXPERIMENTAL
Intervention: Express patients (111 patients)
Number of subjects: 535
Study 19824074 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy with low-dose peginterferon
Number of subjects: 535
Study 16895823 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (assessments at 4 weeks preoperatively, on the day of surgery, and 2 weeks and 12 months postoperatively)
Number of subjects: 0
Study 16895823 — intervention group
Group type: COMPARATOR
Intervention: Group II (assessments at 2 weeks and 12 months postoperatively)
Number of subjects: 0
Study 15265162 — intervention group
Group type: EXPERIMENTAL
Intervention: oral alfacalcidol 0.25 microg daily
Number of subjects: 60
Study 15265162 — intervention group
Group type: EXPERIMENTAL
Intervention: oral alendronate 5 mg daily
Number of subjects: 60
Study 15265162 — intervention group
Group type: EXPERIMENTAL
Intervention: nasal spray calcitonin 200 IU/day
Number of subjects: 60
Study 15265162 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 10878728 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical record DI (MDI) scoring
Number of subjects: 60
Study 10878728 — intervention group
Group type: COMPARATOR
Intervention: Direct DI (DDI) scoring
Number of subjects: 60
Study 10878728 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI organ system scores
Number of subjects: 60
Study 10878728 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI and DDI total scores comparison
Number of subjects: 60
Study 9365147 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg glyceryl trinitrate
Number of subjects: 20
Study 1804605 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylestriol 2 mg every 2 weeks for 1 year
Number of subjects: 90
Study 1804605 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylestriol 2 mg every 2 weeks for 1 year with medroxyprogesterone acetate 6 mg daily for 7 days at the end of treatment
Number of subjects: 90
Study 6321282 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran 18 g/day
Number of subjects: 6
Study 6321282 — intervention group
Group type: COMPARATOR
Intervention: Placebo 18 g/day
Number of subjects: 6
Study 31655571 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based aftercare intervention involving two meetings with a mental health clinician and follow-up contacts by peer workers for four weeks (with an option to extend to 12 weeks).
Number of subjects: 1340
Study 31655571 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based aftercare intervention.
Number of subjects: 1340
Study 31655571 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control.
Number of subjects: 1340
Study 27876358 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIG; 400mg/kg/day for 5 days)
Number of subjects: 56
Study 27876358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 26941024 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) for 8 weeks
Number of subjects: 57
Study 26941024 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (Control)
Number of subjects: 57
Study 25802345 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-12 supplementation
Number of subjects: 1000
Study 25802345 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 1000
Study 25802345 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin B-12 and folic acid
Number of subjects: 1000
Study 25802345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 23232095 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg (four tablets) single dose
Number of subjects: 121
Study 23232095 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg 12‐hourly x two doses
Number of subjects: 121
Study 23232095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,400 mg (eight tablets) single dose
Number of subjects: 121
Study 23232095 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 121
Study 20044155 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training and nutritional intervention program
Number of subjects: 96
Study 20044155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 96
Study 18551121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (0.05 g/kg fat-free mass)
Number of subjects: 11
Study 18551121 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 11
Study 16491653 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid mixture of omega-3 and -6
Number of subjects: 0
Study 12455450 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (10-20 mg per day)
Number of subjects: 127
Study 10483893 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with oral glutamine supplementation of 30 g/d
Number of subjects: 15
Study 10483893 — intervention group
Group type: COMPARATOR
Intervention: TPN with conventional glutamine-free amino acid solution
Number of subjects: 15
Study 10483893 — intervention group
Group type: COMPARATOR
Intervention: Oral intake of normal food
Number of subjects: 15
Study 8738682 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of paracetamol 800 mg plus codeine 60 mg
Number of subjects: 108
Study 8738682 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1000 mg
Number of subjects: 108
Study 8738682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 1683338 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 0
Study 1683338 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 333516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2
Number of subjects: 50
Study 333516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30502569 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic ability trainer (KAT 2000) training group (Group 1)
Number of subjects: 90
Study 30502569 — intervention group
Group type: EXPERIMENTAL
Intervention: Flamingo training group (Group 2)
Number of subjects: 90
Study 30502569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training group (Group 3)
Number of subjects: 90
Study 30502569 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 28036322 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral rotational taping
Number of subjects: 24
Study 26121679 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-DNA ID with Electroporation (EP)
Number of subjects: 25
Study 26121679 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-DNA ID without Electroporation (EP)
Number of subjects: 25
Study 26121679 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-MVA or HIV-MVA+gp140
Number of subjects: 25
Study 26121679 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-DNA ID with or without EP
Number of subjects: 25
Study 26121679 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-MVA+/−gp140
Number of subjects: 25
Study 26121679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 23330658 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 4 mg/day
Number of subjects: 108
Study 23330658 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 2.5 mg/day
Number of subjects: 108
Study 23330658 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from other ARBs to Candesartan
Number of subjects: 108
Study 21665105 — intervention group
Group type: EXPERIMENTAL
Intervention: Device (holographic technology wristband)
Number of subjects: 42
Study 21665105 — intervention group
Group type: COMPARATOR
Intervention: Placebo (silicone wristband with stainless steel discs)
Number of subjects: 42
Study 19309197 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (C-CT)
Number of subjects: 84
Study 19309197 — intervention group
Group type: COMPARATOR
Intervention: Assessment control
Number of subjects: 84